Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Gut Microbes ; 7(3): 246-61, 2016 05 03.
Article in English | MEDLINE | ID: mdl-27007819

ABSTRACT

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used classes of medications in the world. Unfortunately, NSAIDs induce an enteropathy associated with high morbidity and mortality. Although the pathophysiology of this condition involves the interaction of the gut epithelium, microbiota, and NSAIDs, the precise mechanisms by which microbiota influence NSAID enteropathy are unclear. One possible mechanism is that the microbiota may attenuate the severity of disease by specific metabolite-mediated regulation of host inflammation and injury. The microbiota-derived tryptophan-metabolite indole is abundant in the healthy mammalian gut and positively influences intestinal health. We thus examined the effects of indole administration on NSAID enteropathy. Mice (n = 5 per group) were treated once daily for 7 days with an NSAID (indomethacin; 5 mg/kg), indole (20 mg/kg), indomethacin plus indole, or vehicle only (control). Outcomes compared among groups included: microscopic pathology; fecal calprotectin concentration; proportion of neutrophils in the spleen and mesenteric lymph nodes; fecal microbiota composition and diversity; small intestinal mucosal transcriptome; and, fecal tryptophan metabolites. Co-administration of indole with indomethacin: significantly reduced mucosal pathology scores, fecal calprotectin concentrations, and neutrophilic infiltration of the spleen and mesenteric lymph nodes induced by indomethacin; modulated NSAID-induced perturbation of the microbiota, fecal metabolites, and inferred metagenome; and, abrogated a pro-inflammatory gene expression profile in the small intestinal mucosa induced by indomethacin. The microbiota-derived metabolite indole attenuated multiple deleterious effects of NSAID enteropathy, including modulating inflammation mediated by innate immune responses and altering indomethacin-induced shift of the microbiota.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents/metabolism , Enteritis/drug therapy , Gastrointestinal Agents/pharmacology , Indoles/metabolism , Indoles/pharmacology , Inflammation/pathology , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Bacteria/classification , Bacteria/isolation & purification , Biota , Disease Models, Animal , Enteritis/chemically induced , Feces/chemistry , Feces/microbiology , Gastrointestinal Agents/administration & dosage , Histocytochemistry , Indoles/administration & dosage , Leukocyte L1 Antigen Complex/analysis , Lymph Nodes/pathology , Mice , Neutrophils/immunology , Spleen/pathology , Treatment Outcome
2.
Philos Trans R Soc Lond B Biol Sci ; 365(1548): 1931-41, 2010 Jun 27.
Article in English | MEDLINE | ID: mdl-20478888

ABSTRACT

We study the epidemiology of a viral disease with dose-dependent replication and transmission by nesting a differential-equation model of the within-host viral dynamics inside a between-host epidemiological model. We use two complementary approaches for nesting the models: an agent-based (AB) simulation and a mean-field approximation called the growth-matrix (GM) model. We find that although infection rates and predicted case loads are somewhat different between the AB and GM models, several epidemiological parameters, e.g. mean immunity in the population and mean dose received, behave similarly across the methods. Further, through a comparison of our dose-dependent replication model against two control models that uncouple dose-dependent replication from transmission, we find that host immunity in a population after an epidemic is qualitatively different than when transmission depends on time-varying viral abundances within hosts. These results show that within-host dynamics and viral dose should not be neglected in epidemiological models, and that the simpler GM approach to model nesting provides a reasonable tradeoff between model complexity and accuracy of results.


Subject(s)
Disease Outbreaks , Dose-Response Relationship, Immunologic , Models, Immunological , Virus Diseases/immunology , Viruses/immunology , Computer Simulation , Host-Pathogen Interactions/immunology , Humans , Stochastic Processes , Virus Diseases/transmission , Virus Diseases/virology
3.
J Theor Biol ; 261(1): 67-73, 2009 Nov 07.
Article in English | MEDLINE | ID: mdl-19627995

ABSTRACT

We analyze how lethal mutagenesis operates in a compartmentalized host. We assume that different compartments receive different amounts of mutagen and that virions can migrate among compartments. We address two main questions: (1) To what extent can refugia, i.e., compartments that receive little mutagen, prevent extinction? (2) Does migration among compartments limit the effectiveness of refugia? We find that if there is little migration, extinction has to be achieved separately in all compartments. In this case, the total dose of mutagen administered to the host needs to be so high that the mutagen is effective even in the refugia. By contrast, if migration is extensive, then lethal mutagenesis is effective as long as the average growth in all compartments is reduced to below replacement levels. The effectiveness of migration is governed by the ratio of virion replication and death rates, R(0). The smaller R(0), the less migration is necessary to neutralize refugia and the less mutagen is necessary to achieve extinction at high migration rates.


Subject(s)
Models, Biological , Mutagenesis , Mutagens/pharmacokinetics , Viruses/genetics , Antiviral Agents/pharmacokinetics , Antiviral Agents/pharmacology , Humans , Mutagens/pharmacology , Virion/physiology , Virus Replication , Viruses/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...